文献速递银屑病与炎症性皮肤病

古塞奇尤单抗治疗中重度化脓性汗腺炎:2期随机研究

Guselkumab for the treatment of patients with moderate-to-severe hidradenitis suppurativa: A phase 2 randomized study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-06-27

这项2期多中心随机双盲安慰剂对照概念验证研究评估古塞奇尤单抗治疗中重度化脓性汗腺炎的疗效。第16周HiSCR在皮下组50.8%、静脉组45.0%、安慰剂组38.7%,数值上更高但未达统计学显著。主要终点未达到,总体结果不支持古塞奇尤单抗治疗化脓性汗腺炎的疗效。

要点

  • 第16周HiSCR:皮下组50.8% vs 静脉组45.0% vs 安慰剂组38.7%,未达统计学显著。
  • 患者报告结局在皮下组和静脉组较安慰剂组有数值上更大改善。
  • 截至第40周,HiSCR和患者报告结局未见提示剂量反应的明确差异。

核心结论

  • 尽管有适度改善,主要终点未达到,总体结果不支持古塞奇尤单抗治疗化脓性汗腺炎的疗效。

研究设计与样本

  • 2期、多中心、随机、安慰剂对照、双盲、概念验证研究,纳入≥18岁、中重度化脓性汗腺炎≥1年的患者。
  • 患者随机分为三组:古塞奇尤单抗200 mg皮下注射每4周至第36周;古塞奇尤单抗1200 mg静脉注射每4周共12周后自第12周转为200 mg皮下注射每4周至第36周;安慰剂12周后重新随机至200 mg皮下注射每4周(第16–36周)或100 mg皮下注射(第16、20、28、36周,第24、32周安慰剂)。

主要发现

  • 第16周HiSCR:古塞奇尤单抗皮下组50.8% vs 静脉组45.0% vs 安慰剂组38.7%,未达到统计学显著性。
  • 第16周患者报告结局:古塞奇尤单抗皮下组和静脉组较安慰剂组有数值上更大改善。
  • 截至第40周,HiSCR和患者报告结局未见提示剂量反应的明确差异。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition that causes substantial physical, emotional and psychological burdens. Guselkumab, a monoclonal antibody that binds to the p19 subunit of interleukin-23, has demonstrated high levels of efficacy in the treatment of inflammatory diseases, including psoriasis and psoriatic arthritis. OBJECTIVE: To evaluate the effect of guselkumab on the treatment of HS, a phase 2, multicentre, randomized, placebo-controlled, double-blind, proof-of-concept study was conducted. METHODS: Patients ≥18 years of age with moderate-to-severe HS for ≥1 year were randomized to (1) guselkumab 200 mg by subcutaneous (SC) injection every 4 weeks (q4w) through Week 36 (guselkumab SC); (2) guselkumab 1200 mg intravenously (IV) q4w for 12 weeks, then switched to guselkumab 200 mg SC q4w from Weeks 12 through 36 (guselkumab IV); or (3) placebo for 12 weeks, with re-randomization to guselkumab 200 mg SC q4w at Weeks 16 through 36 (placebo → guselkumab 200 mg) or guselkumab 100 mg SC at Weeks 16, 20, 28 and 36 and placebo at Weeks 24 and 32 (placebo → guselkumab 100 mg). End points included HS clinical response (HiSCR) and patient-reported outcomes. RESULTS: Although guselkumab SC or guselkumab IV resulted in numerically higher HiSCR versus placebo at Week 16 (50.8%, 45.0%, 38.7%, respectively), statistical significance was not achieved. Numerically greater improvements in patient-reported outcomes were also observed for guselkumab SC and guselkumab IV versus placebo at Week 16. Through Week 40, no clear differences to suggest a dose response were observed for HiSCR and patient-reported outcomes. CONCLUSIONS: Despite modest improvements, the primary end point was not met and the overall findings do not support the efficacy of guselkumab in the treatment of HS. CLINICALTRIALS: gov: NCT03628924.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Kimball AB, Podda M, Alavi A, et al. Guselkumab for the treatment of patients with moderate-to-severe hidradenitis suppurativa: A phase 2 randomized study. J Eur Acad Dermatol Venereol. 2023. PMID: 37317022. doi:10.1111/jdv.19252

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。